NEW YORK, N.Y. – Shares of Otonomy rose Wednesday after the biotech drug developer’s initial public offering raised $100 million.
The offering of 6.3 million shares, 1 million more than initially predicted, priced at $16 each, the high end of Otonomy’s estimate. That suggested strong demand for the shares, and the company raised more money than it had expected.
San Diego-based Otonomy Inc. is developing treatments for ear diseases. It plans to use the proceeds of its IPO to get regulatory approval for its antibiotic AuriPro and sell the drug, and to research other products.
Otonomy stock closed up $1.15, or 7.2 per cent, to $17.15 on the Nasdaq. Its ticker symbol is “OTIC.”